Effect of denosumab on healing of femoral trochanteric fracture and rehabilitation

Effect of denosumab on healing of femoral trochanteric fracture and rehabilitation - Denosumab and fracture healing

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031971

Enrollment

100

Registered

2018-04-01

Start date

2017-11-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

femoral trochnanteric fracture

Interventions

Denosumab 60ug subcutaneous injection within one week after surgery 1,25OHD within one week after surgery bisphosphonate monthly drug 1,25OHD within one week after surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: femoral trochanteric fracture

Exclusion criteria

Exclusion criteria: open fracture multiple injuries major nerves or vessels injury bedridden under osteoporotic treatment

Design outcomes

Primary

Measure	Time frame
Callus formation at postoperative 1,2 and 3 months	—

Countries

Japan

Contacts

Public ContactShigeharu Uchiyama

Okaya City Hospital Orthopaedic Surgery

sigeuti@shinshu-u.ac.jp+81263373095

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026